Clinical Trial Update: Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating nasal insulin detemir to address forgetfulness in Alzheimer's disease and mild cognitive impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Insulin detemir (insulin detemir)

Snippet

Sponsor: University of Washington | Conditions: Alzheimer's Disease, Mild Cognitive Impairment | Phase 2 | Status: COMPLETED